A retrospective study investigating the rate of HER2 discordance between primary breast carcinoma and locoregional or metastatic disease
Open Access
- 24 November 2012
- journal article
- Published by Springer Nature in BMC Cancer
- Vol. 12 (1) , 555
Abstract
Overall survival of HER2 positive metastatic breast cancer patients has been significantly improved with inclusion of trastuzumab to chemotherapy. Several studies have demonstrated discordant HER2 status in the primary and metastatic tumour. However, rates of discordance vary considerably in published reports.Keywords
This publication has 20 references indexed in Scilit:
- Loss of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Metastatic Sites of HER2-Overexpressing Primary Breast TumorsJournal of Clinical Oncology, 2012
- Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastasesAnnals of Oncology, 2009
- Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancerAnnals of Oncology, 2009
- Gastrosplenic Fistula From Hodgkin's LymphomaJournal of Clinical Oncology, 2009
- Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 statusBreast Cancer Research, 2007
- Comparison of HER2 status between primary tumor and disseminated tumor cells in␣primary breast cancer patientsBreast Cancer Research and Treatment, 2006
- Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Administered As First-Line Treatment: The M77001 Study GroupJournal of Clinical Oncology, 2005
- Serum HER‐2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapyCancer, 2005
- Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sitesAnnals of Oncology, 2002
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2New England Journal of Medicine, 2001